Investment Thesis
Assembly Biosciences demonstrates strong revenue growth (+153.5% YoY) but is burning significant cash with negative operating income, negative free cash flow of -$41.2M, and deteriorating profitability metrics. Despite a solid balance sheet with $58.5M in cash and low debt, the company's current cash burn rate is unsustainable and threatens long-term viability without achieving profitability or securing additional funding.
ASMB Strengths
- Exceptional revenue growth of 153.5% year-over-year indicates strong commercial traction or successful product launches
- Strong balance sheet with $58.5M in cash, $206.8M stockholders' equity, and minimal debt (0.00x debt-to-equity ratio)
- High liquidity with current ratio of 5.22x provides runway to weather operational challenges
ASMB Risks
- Severe cash burn of -$41.1M in operating cash flow with negative free cash flow margin of -56.9%, indicating revenue growth is not translating to profitability
- Operating margin of -16.8% and net margin of -8.5% show the company is not yet profitable despite substantial revenue, suggesting unsustainable cost structure
- Continued negative operating cash flow at current burn rate would exhaust cash reserves within approximately 1.4 years without achieving profitability or securing additional capital
Key Metrics to Watch
- Path to operating profitability and operating margin expansion
- Operating cash flow trend and time to cash flow breakeven
- Cash burn rate and runway remaining at current burn levels
- Gross margin sustainability as revenue scales
ASMB Financial Metrics
ASMB Profitability Ratios
ASMB Balance Sheet & Liquidity
ASMB 5-Year Financial Trend
5-Year Trend Summary: ASSEMBLY BIOSCIENCES, INC.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-6.69 indicates the company is currently unprofitable.
ASMB Growth Metrics (YoY)
ASMB Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $6.8M | -$9.2M | $-0.72 |
| Q2 2025 | $8.5M | -$10.2M | $-1.33 |
| Q1 2025 | $5.8M | -$8.8M | $-1.17 |
| Q3 2024 | N/A | -$9.6M | $-1.51 |
| Q2 2024 | N/A | -$11.2M | $-1.98 |
| Q1 2024 | N/A | -$9.1M | $-1.66 |
| Q3 2022 | $6.3M | -$18.8M | $-0.41 |
| Q3 2021 | $6.3M | -$3.3M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ASMB Capital Allocation
ASMB SEC Filings
Access official SEC EDGAR filings for ASSEMBLY BIOSCIENCES, INC. (CIK: 0001426800)